Chronic myeloid leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• ABL1 12
• TP53 1
• JAK 1
• AKT 0
• IDH 4
• ERK 0
• FLT3 2
• PI3K 0
• JNK 0
• STAT3 0
• BCL-2 2
• CD19 1
• HSP90 0
• KIT 1
• PDGFR 0
• CSF1R 2
• HDAC 0
• HIF-1 0
• IL-1 2
• MAPK 0
• PPAR 0
• AMPK 0
• CD123 0
• CD38 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• mTOR 0
• NLRP3 0
• NRF2 0
• RAS 0
• RUNX1 0
• BTK 0
• CD20 0
• CD22 0
• CD33 0
• CD40 0
• CD47 1
• CTLA-4 0
• CXCR4 0
• G6PD 0
• GLP-1 0
• IL-15 0
• IL-6 1
• KRAS 0
• MEK 1
• MYC 0
• NPM1 0
• NRAS 0
• PD-1 0
• PRMT5 0
• PTEN 0
• SGLT2 0
• SIRT1 0
• TIM-3 0
• YAP 0

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  The Role of Cell Competition in Shaping the Clonal Structure of Hematopoiesis

  Washington University· Saint Louis, United States· US$465,749 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · K99

  The Epitranscriptomic-Microtubule Axis as a Novel Mechanism of Ponatinib induced Cardiotoxicity

  University of Illinois at Chicago· Chicago, United States· US$139,113 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R21

  Interferon-γ in combination with donor leukocyte infusion to treat relapsed acute myeloid leukemia and myelodysplastic syndromes after haploidentical donor stem cell transplantation

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$408,829 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · F31

  Role of ABL kinases in regulating DNA damage repair and transcription-replication conflicts in SCLC tumors

  Duke University· Durham, United States· US$43,742 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · F30

  From Resistance to Innovation: Towards Countering Asciminib Resistance and Designing Next-Generation Allosteric Inhibitors against CML

  State University New York Stony Brook· Stony Brook, United States· US$42,647 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon 2020) · ERC-STG

  Functional Interrogation of Non-coding DNA Sequences in leukemia development and drug resistance (FIND-seq)

  St. Anna Kinderkrebsforschung Gmbh· Wien, Austria· EU contribution €1,784,000· until Aug 2027

  The disease is named only in the funder's project summary, not in the title.

6 of 51 running projects, newest first. Listed amounts together: US$33.5m + €1.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

  NCT04477291· Aptose Biosciences Inc.· Updated 7 Mar 2025

  “Change in corporate strategy”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 2
• Gene Expression Profiling 6
• Sequence Analysis, RNA 2
• Exome Sequencing 1
• Proteomics 5
• Metabolomics 3
• Mass Spectrometry 2
• Flow Cytometry 13
• Xenograft Model Antitumor Assays 19
• Magnetic Resonance Imaging 4
• Machine Learning 3
• Cohort Studies 9
• Genome-Wide Association Study 3

• Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population-based cohort study.

  Alzheimers Dement, Oct 2026

• Impact of Somatic Mutations on Treatment Response and Resistance in Chronic Myeloid Leukemia.

  Int J Lab Hematol, Jun 2026

• Philadelphia chromosome-negative but BCR::ABL1-positive acute lymphoblastic leukemia: a real-world multicenter cohort study.

  Int J Hematol, Apr 2026

• Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study.

  Ann Hematol, Apr 2026

• Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.

  BMC Cancer, Feb 2026

• Ponatinib for CML patients in routine clinical practice: the PONDEROSA study.

  Ann Hematol, Jan 2026

• Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study.

  Br J Haematol, Jan 2026

• Impact of BCL3 Expression and Clinical-Hematologic Risk Factors on Early Molecular Response, Reticulin Fibrosis, and Survival Outcomes in Chronic Myeloid Leukemia: A Prognostic Cohort Study.

  Clin Ter, Jan 2026

• The association between vitamin C and vitamin E supplement use before hematopoietic stem cell transplant and outcomes to two years.

  J Am Diet Assoc, Aug 2003

See which targets of this disease your abstract mentions, and go to the people working on them.